ECSP14024494A - Anticuerpos frente a los Ligandos del receptor B1 de bradicinina - Google Patents

Anticuerpos frente a los Ligandos del receptor B1 de bradicinina

Info

Publication number
ECSP14024494A
ECSP14024494A ECIEPI201424494A ECPI201424494A ECSP14024494A EC SP14024494 A ECSP14024494 A EC SP14024494A EC IEPI201424494 A ECIEPI201424494 A EC IEPI201424494A EC PI201424494 A ECPI201424494 A EC PI201424494A EC SP14024494 A ECSP14024494 A EC SP14024494A
Authority
EC
Ecuador
Prior art keywords
kallidin
antibodies
des
arg10
bradykinin
Prior art date
Application number
ECIEPI201424494A
Other languages
English (en)
Inventor
Matthew Davidson
Xin Chen
Han Li
Jie Zhang
Alla Pritsker
Nicolas Baurin
Govindan Subramanian
Dorothea KOMINOS
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ECSP14024494A publication Critical patent/ECSP14024494A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Resumen: La invención proporciona anticuerpos que se unen específicamente a calidina o des-Arg10-calidina. La invención proporciona también composiciones farmacéuticas, así como ácido nucleicos que codifican anticuerpos anti-calidina o anti des-Arg10-calidina, vectores de expresión recombinantes y células hospedantes para producir dichos anticuerpos, o fragmentos de los mismos. También son proporcionados por la invención métodos de uso de los anticuerpos de la invención para modular la actividad de la calidina o des-Arg10-calidina o para detectar la calidina o la des-Arg10-calidina, ya sea in vitro o in vivo. La invención proporciona además métodos para producir anticuerpos que se unen específicamente a des-Arg9- bradicinina y a un péptido tipo des-Arg10-calidina.
ECIEPI201424494A 2012-03-28 2014-10-27 Anticuerpos frente a los Ligandos del receptor B1 de bradicinina ECSP14024494A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261616845P 2012-03-28 2012-03-28
FR1350953 2013-02-04

Publications (1)

Publication Number Publication Date
ECSP14024494A true ECSP14024494A (es) 2015-09-30

Family

ID=73005822

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201424494A ECSP14024494A (es) 2012-03-28 2014-10-27 Anticuerpos frente a los Ligandos del receptor B1 de bradicinina

Country Status (1)

Country Link
EC (1) ECSP14024494A (es)

Similar Documents

Publication Publication Date Title
DOP2014000199A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
CR20160117A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
PE20180672A1 (es) Anticuerpos anti-ctla-4 y metodos de uso de los mismos
UY32971A (es) Proteínas de unión al antígeno de la il-23 humana
CR20150258A (es) Anticuerpos anti-ceacam5 y usos de éstos
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
SG10201900948PA (en) Modified nucleotide linkers
MY175708A (en) Dna antibody constructs and method of using same
MX2016007063A (es) Peptidos terapeuticos.
EA201991409A2 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
BR112014002817A2 (pt) Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62
PE20160528A1 (es) Anticuerpos
CO6680702A2 (es) Péptido o complejo péptido que se une a integrina alfa 2 y metodos y sus usos que implican a los mismos
AR080680A1 (es) Proteinas de union a basigina
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
MX2016004754A (es) Nuevo peptido que tiene cuatro epitopos de linfocitos t citotoxicos (ctl) enlazados.
ECSP14024494A (es) Anticuerpos frente a los Ligandos del receptor B1 de bradicinina
PH12014502182A1 (en) Methods and compositions for modulating notch activity
TN2014000395A1 (en) Antibodies to bradykinin b1 receptor ligands
EA201792665A1 (ru) Антитела против ctla-4 и способы их применения
AR101757A1 (es) Anticuerpos anti-mfi2 y métodos de uso
AR103294A1 (es) Composiciones y procedimientos para la glicosilación de proteínas
AR097319A1 (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos